Clene Inc. to Present at D. Boral Capital Global Conference in New York
Clene Inc., a late clinical-stage biopharmaceutical company developing neurological disease treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors an opportunity to learn about its innovative research and potential therapeutics.
Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company focused on neurological disease treatments, will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference presents a significant opportunity for investors and industry analysts to gain insights into the company's groundbreaking work in neurodegenerative disease research.
President and CEO Rob Etherington will be available for one-on-one meetings throughout the day, providing direct access for potential investors and stakeholders to discuss the company's innovative CNM-Au8® therapy. This investigational treatment targets mitochondrial health and neuronal function, with potential applications in treating conditions such as amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.
The conference provides a strategic platform for Clene to showcase its research targeting central nervous system cell survival and function. By focusing on mitochondrial function and the NAD pathway while reducing oxidative stress, the company is positioning itself at the forefront of neurological disease treatment innovation.